Phase III Pipelines Running Dry; Bristol Looks Relatively Flush In 2004
Executive Summary
Bristol-Myers Squibb appears to have one of the healthier late-stage product development pipelines heading into 2004
You may also be interested in...
Bristol Late-Stage Pipeline Reflects Success Of In-House Development
Bristol-Myers Squibb's late-stage pipeline will include 80% internally developed agents, with three of those compounds moving into Phase III
Bristol Late-Stage Pipeline Reflects Success Of In-House Development
Bristol-Myers Squibb's late-stage pipeline will include 80% internally developed agents, with three of those compounds moving into Phase III
Sanofi To Move Two NMEs Into Phase III In 2004, For Total Of Nine
Sanofi-Synthelabo plans to move two new molecular entities into Phase III during 2004